Novo Nordisk Partnership
3 articles on Novo Nordisk Partnership, written by Shotlee and medically reviewed for clinical accuracy.
Emcure Drops Poviztra Semaglutide Starting Dose Price by 55%
Emcure Pharmaceuticals has reduced the price of its semaglutide injection Poviztra by 55% for the starting dose, now at ₹3,999 per month. This move, in partnership with Novo Nordisk, follows recent price slashes on Wegovy and Ozempic and the launch of Indian generics. It aims to tackle India's growing obesity epidemic affecting over 600 million adults.
5 min read
Hims & Hers Opens $149 Wegovy & Ozempic Waitlist via Novo Deal
Hims & Hers Health (NYSE: HIMS) is now offering a waitlist for affordable branded Wegovy and Ozempic at $149, thanks to a new Novo Nordisk deal. This expands access to these popular GLP-1 weight-loss drugs amid high demand. Meanwhile, HIMS stock shows short-term rebound potential in a downtrend—dive into the technicals and analyst views.
5 min read
Novo Nordisk Expands Ozempic, Wegovy Testing on Adolescents
Novo Nordisk, maker of Ozempic and Wegovy, has launched a three-year research partnership to test weight-loss GLP-1 drugs on adolescents in Pacific Island nations, beginning in Fiji. Announced amid a Danish royal visit, this move addresses the obesity 'ticking bomb' threatening kids' lifespans. CEO Mike Doustdar urges bolder action on prevention and access.
5 min read